Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease.

Ager RR, Fonseca MI, Chu SH, Sanderson SD, Taylor SM, Woodruff TM, Tenner AJ.

J Neurochem. 2010 Apr;113(2):389-401. doi: 10.1111/j.1471-4159.2010.06595.x. Epub 2010 Feb 2.

2.

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, Zheng H.

J Neurosci. 2016 Jan 13;36(2):577-89. doi: 10.1523/JNEUROSCI.2117-15.2016.

3.

Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.

Cameron B, Tse W, Lamb R, Li X, Lamb BT, Landreth GE.

J Neurosci. 2012 Oct 24;32(43):15112-23. doi: 10.1523/JNEUROSCI.1729-12.2012.

4.

Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.

Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ.

J Immunol. 2009 Jul 15;183(2):1375-83. doi: 10.4049/jimmunol.0901005. Epub 2009 Jun 26.

5.

Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.

Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE.

J Neuroinflammation. 2015 Jan 16;12:7. doi: 10.1186/s12974-014-0229-9.

6.

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.

Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW.

J Neuroinflammation. 2014 Jun 19;11:111. doi: 10.1186/1742-2094-11-111.

7.

Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.

Landlinger C, Oberleitner L, Gruber P, Noiges B, Yatsyk K, Santic R, Mandler M, Staffler G.

J Neuroinflammation. 2015 Aug 16;12:150. doi: 10.1186/s12974-015-0369-6.

8.

Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA.

J Neurosci. 2008 Jun 18;28(25):6333-41. doi: 10.1523/JNEUROSCI.0829-08.2008.

9.

Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology.

Fonseca MI, McGuire SO, Counts SE, Tenner AJ.

J Neuroinflammation. 2013 Feb 8;10:25. doi: 10.1186/1742-2094-10-25.

10.

Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition.

Fan R, DeFilippis K, Van Nostrand WE.

J Neuroinflammation. 2007 Sep 18;4:22.

11.

Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ.

J Neurochem. 2008 Sep;106(5):2080-92. doi: 10.1111/j.1471-4159.2008.05558.x. Epub 2008 Jul 9.

12.

CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer's disease mouse model.

Daschil N, Obermair GJ, Flucher BE, Stefanova N, Hutter-Paier B, Windisch M, Humpel C, Marksteiner J.

J Alzheimers Dis. 2013;37(2):439-51. doi: 10.3233/JAD-130560.

13.

Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model.

Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, LaFerla FM, Olschowka JA, O'Banion MK.

J Neurosci. 2013 Mar 13;33(11):5053-64. doi: 10.1523/JNEUROSCI.4361-12.2013.

14.

Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease.

Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y, Tenner AJ.

J Neuroinflammation. 2011 Jan 15;8(1):4. doi: 10.1186/1742-2094-8-4.

15.

Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies.

Ji B, Maeda J, Sawada M, Ono M, Okauchi T, Inaji M, Zhang MR, Suzuki K, Ando K, Staufenbiel M, Trojanowski JQ, Lee VM, Higuchi M, Suhara T.

J Neurosci. 2008 Nov 19;28(47):12255-67. doi: 10.1523/JNEUROSCI.2312-08.2008.

16.

[The roles of C5a and C5aR antagonist in TNF-α secretion and CD88 expression of BV2 microglial cells treated with Aβ1-42 oligomer].

Yang F, Li D, Xu S.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Mar;29(3):265-8. Chinese.

PMID:
23643083
17.

Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease.

Löffler T, Flunkert S, Havas D, Schweinzer C, Uger M, Windisch M, Steyrer E, Hutter-Paier B.

J Neuroinflammation. 2014 May 1;11:84. doi: 10.1186/1742-2094-11-84.

18.

Early neuronal loss and axonal/presynaptic damage is associated with accelerated amyloid-β accumulation in AβPP/PS1 Alzheimer's disease mice subiculum.

Trujillo-Estrada L, Dávila JC, Sánchez-Mejias E, Sánchez-Varo R, Gomez-Arboledas A, Vizuete M, Vitorica J, Gutiérrez A.

J Alzheimers Dis. 2014;42(2):521-41. doi: 10.3233/JAD-140495.

PMID:
24927710
19.

Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.

Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T.

Glia. 2010 Feb;58(3):300-14. doi: 10.1002/glia.20924.

20.

Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice.

Latta CH, Sudduth TL, Weekman EM, Brothers HM, Abner EL, Popa GJ, Mendenhall MD, Gonzalez-Oregon F, Braun K, Wilcock DM.

J Neuroinflammation. 2015 Mar 4;12:41. doi: 10.1186/s12974-015-0243-6.

Supplemental Content

Support Center